These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19327411)

  • 1. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
    Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
    Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.
    da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF
    Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
    Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.
    Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    FEBS Lett; 2011 Jun; 585(12):1884-90. PubMed ID: 21557940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
    Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
    Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
    Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
    Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.